Taysha gene therapies reports fourth quarter and full year 2021 financial results and provides corporate update

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today reported financial results for the fourth quarter and full-year ended december 31, 2021 and provided a corporate update. “2021 was a year of accomplishment that included positive data
TSHA Ratings Summary
TSHA Quant Ranking